First aml patient transplanted with vor bio's trem-cel demonstrated durable engraftment through multiple mylotarg™ cycles at initial dose level

Cambridge, mass., feb. 16, 2023 (globe newswire) -- vor bio (nasdaq: vor), a clinical-stage cell and genome engineering company, presented clinical data from vbp101, its phase 1/2a multicenter, open-label, first-in-human study of trem-cel (previously vor33) in patients with acute myeloid leukemia (aml). in the first patient, trem-cel maintained hematopoiesis through three cycles of mylotarg (gemtuzumab ozogamicin), which was well-tolerated at the initial dose level of 0.5 mg/m2. a second patient has successfully received a trem-cel transplant and engrafted normally. these data were presented today by miguel-angel perales, md, chief, adult bone marrow transplant service, memorial sloan kettering cancer center in a late-breaking poster at the 2023 tandem meetings (transplantation & cellular therapy meetings of astct™ and cibmtr®) in orlando, fl.
VOR Ratings Summary
VOR Quant Ranking